GSK’s Andrew Witty knighted
January 3, 2012Sales and Marketing Andrew Witty, GSK
GlaxoSmithKline chief executive Andrew Witty and former ABPI director general Richard Barker were among the recipients in the 2012 New …
Ben Venue extends plant shutdown
January 3, 2012Manufacturing and Production Ben Venue
Troubled contract manufacturing organisation Ben Venue Laboratories has said it will have to extend its temporary shutdown of a facility …
Pharma manufacturing in brief
January 3, 2012Manufacturing and Production IGI Laboratories, aseptic packaging
Pharma manufacturing news in briefCPL shuts down a facility in New Jersey, US, Tamer plans a new plant in Saudi …
AAIPharma expands in North Carolina
January 3, 2012Manufacturing and Production AAIPharma
AAIPharma Services is planning to expand its contract analytics facility in Wilmington, North Carolina, with a new 40,000 sq. ft. …
Avastin gains EU licence for ovarian cancer
January 3, 2012Sales and Marketing Roche, avastin, ovarian
Roche’s Avastin has been granted a new European licence to treat ovarian cancer, which could help offset falling sales of …
Introducing SHL’s first White Paper: “Auto Injectors: From Planning to Launch”
January 3, 2012Manufacturing and Production auto injector, autoinjector, autoinjector manufacturing, autoinjector white paper, shl white paper
SHL is officially introducing the company’s first White Paper on the topic of “Auto Injectors; From Planning to Launch” with …
Working Life
January 1, 2012Working Life
People working in pharma talking about what they like and dislike most about their jobs Mike Crooks, UK general manager, Astellas
Contract research news in brief
December 23, 2011Manufacturing and Production AMRI, Frontage Labs, Kymos and Crystal3 Labs, Pacific Biomarkers/Cingene
A round up of news in the CRO sector, including cutbacks at AMRI and updates from Pacific Biomarkers/Clingene, Frontage Labs, …
NHS on track to make £358 million in drug savings
December 23, 2011Sales and Marketing DoH, NHS, QIPP
The NHS in England is set to make £358 million in savings from drugs over the financial year, according to …
Ranbaxy sets aside $500m for manufacturing penalties
December 22, 2011Manufacturing and Production
Indian drugmaker Ranbaxy Laboratories has set aside $500 million to pay financial penalties levied by the US FDA, resulting from …
RSA makes three new appointments
December 22, 2011Business Services, Medical Communications, Sales and Marketing rsa
Life sciences recruitment firm RSA has announced three new appointments to its UK office. Dr David Jay joins RSA UK …
FDA accepts Pfizer’s arthritis pill for review
December 22, 2011Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib
The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …
GSK sells off over-the-counter brands
December 22, 2011Sales and Marketing GSK, OTC
GlaxoSmithKline has offloaded a number of OTC consumer health brands in North America for £426 million in cash. Flagged up …
Department of Health slims down agency partners
December 21, 2011Medical Communications DH, Freud Communications, MEC
The Department of Health has stripped back its use of comms agencies in its public health campaigns by switching to …
AstraZeneca takes option on new diabetes candidates
December 21, 2011Sales and Marketing AstraZeneca, diabetes
AstraZeneca and Prosidion, a subsidiary of Astellas have signed a deal giving AstraZeneca an exclusive option to acquire two diabetes …
Caudex Medical makes two senior appointments
December 21, 2011Business Services, Medical Communications, Sales and Marketing Andy Bowman, Caudex Medical, Gary Burd
Andy Bowman and Gary Burd have been appointed to senior positions within the medical communications firm Caudex Medical. Bowman has …
FDA to probe Gilenya patient death
December 21, 2011Sales and Marketing FDA, Novartis, gilenya
The FDA is investigating Novartis’s new multiple sclerosis treatment Gilenya after a patient died within hours of taking the drug. …
Xarelto gains new licences in UK
December 20, 2011Sales and Marketing
Bayer’s anticoagulant pill Xarelto has gained two new lucrative licences, and is now available in the UK to prevent stroke …
AstraZeneca, Novo and Enlight sign collaborative research deal
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, Enlight, Novo Nordisk
AstraZeneca and Novo Nordisk have linked up with a US biosciences firm in a bid to enhance their R&D operations. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
